Solid Tumor Antigens

Cat. No.

AT0588

CAS No.

558480-40-3

Volociximab

Synonyms: M200; Eos 200-4

Volociximab (M200), a chimeric human/murine IgG4 monoclonal antibody, selectively targets integrin α5β1 with an EC50 of 0.2 nM. Integrin α5β1, a principal receptor for fibronectin, plays a crucial role in angiogenesis. Volociximab exhibits potent antiangiogenic and antitumor properties, effectively inhibiting the proliferation of human umbilical vein vascular endothelial cells (HUVECs). This antibody is instrumental in research focused on the mechanisms of angiogenesis and potential therapeutic strategies for cancer treatment.

Cat. No.

AT0607

CAS No.

144058-40-2

Satumomab

Satumomab is a monoclonal antibody of the IgG4-G2a κ isotype, specifically targeting the tumor-associated glycoprotein 72 (TAG-72). This antibody is designed for the precise detection and study of TAG-72 expression in various cancer types, facilitating research into tumor biology and potential therapeutic targets.

Cat. No.

AT0618

CAS No.

1496553-00-4

Zolbetuximab

Synonyms: IMAB362

Zolbetuximab (IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2, a tight junction protein predominantly expressed in certain epithelial cells. This antibody facilitates the selective eradication of Claudin-18.2-positive cells by engaging immune effector mechanisms. It is primarily utilized in scientific studies focused on gastrointestinal adenocarcinomas and pancreatic tumors, offering a critical tool for understanding and potentially targeting these malignancies.

Cat. No.

AT0622

CAS No.

912628-39-8

Drozitumab

Synonyms: PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody

Drozitumab (PRO 95780) is a human agonistic monoclonal antibody designed to specifically target and bind to the death receptor DR5. This interaction promotes apoptosis in tumor cells, thereby exhibiting potent antitumor activity. Drozitumab has demonstrated significant efficacy against rhabdomyosarcoma in research settings, making it a valuable tool for studies focused on this type of cancer.

Cat. No.

AT0623

Anti-CLDN6 Antibody (DS-9606A antibody)

The Anti-CLDN6 Antibody (DS-9606A) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells that specifically targets Claudin 6 (CLDN6). This antibody is composed of an IgG1 type heavy chain and a human kappa (huκ) type light chain, with a predicted molecular weight of 145.84 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is ideal for research applications focusing on the role of CLDN6 in cellular tight junctions and its implications in various disease states.

Cat. No.

AT0636

CAS No.

2415259-90-2

Ulenistamab

Synonyms: PBP1510

Ulenistamab (PBP1510) is a pioneering humanized IgG1 monoclonal antibody designed to specifically target the pancreatic adenocarcinoma upregulated factor (PAUF). This antibody serves as a vital tool in the investigation of pancreatic cancer (PC), offering potential insights into disease mechanisms and therapeutic avenues.

Cat. No.

AT0650

MB-311

MB-311 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Lewis Y antigen. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, with an approximate molecular weight of 150 kDa. For isotype control experiments, the Human IgG1 kappa, Isotype Control is recommended. MB-311 is applicable in a range of research settings where the Lewis Y antigen is a focus of study.

Cat. No.

AT0664

CAS No.

2975630-15-8

Torvutatug

Torvutatug is a human IgG1 κ monoclonal antibody targeting FOLR1. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Cat. No.

AT0693

CAS No.

1613313-01-1

Rovalpituzumab

Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3), a protein expressed in neuroendocrine tumors including small cell lung cancer (SCLC). This antibody serves as a foundational component in the development of the antibody-drug conjugate (ADC), Rovalpituzumab Tesirine, designed for targeted cancer therapy. Rovalpituzumab exhibits specific activity against SCLC, providing a strategic tool for research and therapeutic development in oncology.

Cat. No.

AT0695

CAS No.

2254118-43-7

Upifitamab

Upifitamab serves as an ADC (antibody-drug conjugate) antibody, specifically the unconjugated form of upifitamab rilsodotin, designed for the synthesis of antibody-coupled agents. Upifitamab rilsodotin targets the sodium-dependent phosphate transport protein 2b (NaPi2b), and is predominantly utilized in the study of platinum-resistant recurrent ovarian cancer. This application highlights its potential in advancing therapeutic strategies and understanding disease mechanisms in oncology research.

Cat. No.

AT0714

hT84.66-M5A

hT84.66-M5A is a humanized IgG1 monoclonal antibody specifically designed to target the carcinoembryonic antigen (CEA), a widely studied tumor marker implicated in various types of cancers. This antibody mimics the natural immune response against tumor cells expressing CEA, making it an essential tool for research in oncology and cancer diagnostics. The recommended isotype control for hT84.66-M5A is Human IgG1 kappa, which serves as a critical baseline to validate the specificity and ensure the accuracy of immunoassays involving this antibody.

Cat. No.

AT0727

CAS No.

2307488-83-9

Tarlatamab

Synonyms: AMG-757

Tarlatamab (AMG-757) is a first-in-class, half-life extended (HLE) bispecific T-cell engager (BiTE) antibody designed for targeted immuno-oncology applications. This therapeutic antibody specifically targets delta-like ligand 3 (DLL3), a protein predominantly expressed in small-cell lung cancer (SCLC) cells, with minimal expression in healthy tissues. Tarlatamab exhibits high binding affinities with dissociation constants (K_Ds) of 0.64 nM for human DLL3 and 0.50 nM for nonhuman primate (NHP) DLL3. Additionally, it shows binding affinities of 14.9 nM and 12 nM for human and NHP CD3, respectively. The selective targeting of DLL3 and the engagement of CD3, a critical component of the T-cell receptor complex, make Tarlatamab a promising candidate for the study and potential treatment of SCLC.

Cat. No.

AT0737

CAS No.

2109730-69-8

Benufutamab

Synonyms: GEN1029

Benufutamab (GEN1029) is an agonistic antibody targeting death receptor 5 (DR5), designed to selectively initiate apoptosis in tumor cells. This biologic is composed of two non-competing, DR5-specific IgG1 antibodies, each engineered with an E430G mutation in the Fc domain to enhance its therapeutic efficacy. Benufutamab demonstrates significant antitumor activity, making it a valuable tool for research in cancer therapy and apoptosis mechanisms.

Cat. No.

AT0744

CAS No.

2767203-01-8

Misitatug

Misitatug is a chimeric antibody of the IgG1κ isotype, specifically designed to target mesothelin (MSLN). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0752

CAS No.

1629760-28-6

Ladiratuzumab

Synonyms: hLIV22

Ladiratuzumab (hLIV22) is a humanized monoclonal antibody specifically targeting the zinc transporter LIV-1/ZIP6. This antibody is chemically linked to monomethyl auristatin E (MMAE) through a cleavable dipeptide linker, forming the antibody-drug conjugate (ADC) known as Ladiratuzumab vedotin. Designed for precision in oncological therapies, Ladiratuzumab vedotin binds selectively to the LIV-1 protein, which is frequently overexpressed on the surface of various tumor cells. Upon binding, the conjugate is internalized via receptor-mediated endocytosis, facilitating the intracellular release of MMAE. This potent cytotoxic agent acts by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis of the tumor cells. Additionally, Ladiratuzumab vedotin exhibits a bystander effect, where the cytotoxic agent can diffuse and eliminate neighboring tumor cells, enhancing its therapeutic efficacy. This ADC is particularly relevant in research focused on solid tumors, including metastatic triple-negative breast cancer (mTNBC), where conventional treatments often fall short.

Cat. No.

AT0773

CAS No.

2610074-56-9

Raludotatug

Raludotatug is a humanized IgG1-kappa monoclonal antibody targeting CDH6, designed for antineoplastic applications. This therapeutic antibody binds specifically to CDH6, a protein implicated in the progression of certain cancers, thereby inhibiting tumor growth and proliferation. Raludotatug's mechanism of action and specificity make it a valuable tool for research and potential therapeutic interventions in oncology.

Cat. No.

AT0802

Anti-FOLR1/FRA Antibody

The Anti-FOLR1/FRA Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the FOLR1/FRA protein. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 146.46 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is applicable for use in various immunological assays to study the role and expression of the FOLR1/FRA protein in biological systems.

Cat. No.

AT0810

CAS No.

339086-80-5

Tadocizumab

Synonyms: C4G1; YM-337

Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody designed to target integrin αIIbβ3. It exhibits potent antiplatelet and antithrombotic properties, making it an ideal candidate for research into cardiovascular diseases. Tadocizumab's specificity for integrin αIIbβ3 allows for the study of this integrin's role in platelet aggregation and thrombus formation, providing valuable insights into potential therapeutic approaches for thrombotic disorders.

Cat. No.

AT0811

CAS No.

219649-07-7

Labetuzumab

Labetuzumab is a humanized monoclonal antibody targeting the carcinoembryonic antigen (CEA), known for its role in inhibiting tumor growth. This antibody has demonstrated efficacy in sensitizing human medullary thyroid cancer xenografts to Dacarbazine, enhancing the chemotherapeutic response. Labetuzumab is utilized primarily in research focused on the treatment and mechanistic understanding of cancer progression and therapy resistance.

Cat. No.

AT0813

CAS No.

2267989-53-5

Datopotamab

Datopotamab (CDP7657) is a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2). This antibody serves as a foundational component for the development of antibody-drug conjugates (ADCs), particularly when conjugated with the DNA topoisomerase I inhibitor, Deruxtecan. Datopotamab is primarily utilized in research focused on triple-negative breast cancer and non-small cell lung cancer, providing a valuable tool for investigating therapeutic avenues in these challenging oncological contexts.

Cat. No.

AT0823

CAS No.

931402-35-6

Amatuximab

Synonyms: MORab-009

Amatuximab (MORab-009) is a chimeric, humanized IgG1/k monoclonal antibody designed to specifically target mesothelin (MSLN), a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein. Mesothelin is expressed in a limited range of normal adult tissues, predominantly in the mesothelium. This antibody binds to the cell surface mesothelin, making it a valuable tool for research into mesothelin's role in various biological processes and diseases.

Cat. No.

AT0835

CAS No.

2414550-93-7

Pelgifatamab

Synonyms: BAY-2315497; PSMA-TTC

Pelgifatamab (BAY-2315497) is a monoclonal antibody targeting the prostate-specific membrane antigen (PSMA). This antibody can be covalently attached to a 225Ac binding moiety, making it a valuable tool for research into metastatic castration-resistant prostate cancer (mCRPC). Pelgifatamab's specificity for PSMA and its potential for radioisotope conjugation facilitate its use in advanced prostate cancer studies, particularly in therapeutic research and radiolabeled imaging applications.

Cat. No.

AT0851

CAS No.

2862919-81-9

Bulumtatug

Bulumtatug is a human IgG1κ monoclonal antibody targeting Nectin-4. The recommended isotype control for experimental use is Human IgG1 kappa Isotype Control.

Cat. No.

AT0867

CAS No.

2260767-49-3

Rosopatamab

Synonyms: HUJ-591

Rosopatamab (HuJ591) is a humanized IgG1 monoclonal antibody targeting the Prostate-Specific Membrane Antigen (PSMA). This antibody is specifically designed for use in cancer research, with a particular focus on prostate cancer. Rosopatamab can be conjugated to lutetium-177 (177Lu), a low-energy beta-emitting radioisotope, via the bifunctional chelator DOTA-NHS ester. This conjugation facilitates the creation of a radioimmunoconjugate that selectively targets and efficiently eradicates malignant prostate cells. This specificity and efficiency make Rosopatamab an invaluable tool in the development of targeted radiotherapeutic strategies in oncology research.

Cat. No.

AT0868

Anti-TM4SF1 Antibody (AGX-A07)

The Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody specifically designed to target TM4SF1, a transmembrane protein implicated in cell signaling and tumor cell proliferation. For optimal use in experimental controls, it is recommended to utilize Human IgG1 kappa as an isotype control. This antibody serves as a valuable tool in research focused on cancer biology and therapeutic development.